Drug Trial Radar · NCT01278342
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
Last checked: Nov 20, 2026Latest source record: Mar 3, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Sep 2006
Primary completion
Nov 2009
Study completion Nov 2009
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 17, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy of 8 months treatment of Sandostatin® LAR® High Dose monotherapy or Sandostatin® LAR® High Dose in combination either with growth hormone antagonist or dopamine agonist to control biochemical parameters (GH and insulin-like growth factor I \[IGF I\]) of acromegalic patients not achieving biochemical normalization at conventional regimen.
Conditions
- Acromegaly
Interventions
Sandostatin LARDrug
40 mg intramuscular (i.m.) every 28 days for 3 months
pegvisomantDrug
Weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for 4 months given with Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months
cabergolineDrug
Weekly cabergoline for 4 months, with weekly doses of Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months. Cabergoline doses as follows: 1. st week: 0.25 mg twice a week (0.50 mg/week) 2. nd week: 0.50 mg/week twice a week (1 mg/week) 3. rd week: 0.50 mg four times a week (2 mg/week) 4. th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Percentage of Participants With Complete Response (CR) at 8 MonthsTime frame: From Baseline to 8 months
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Bron, France
Novartis Investigative Site
Le Kremlin-Bicêtre, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Nîmes, France
Novartis Investigative Site
Pessac, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Genova, Italy
Novartis Investigative Site
Naples, Italy
Novarts Investigative Site
Naples, Italy
Novartis Investigative Site
Padova, Italy
Novartis Investigative Site
Perugia, Italy
Novartis Investigative Site
Pisa, Italy
Novartis Investigative Site
Torino, Italy
Novartis Investigative Site
Lodz, Poland
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Wroclaw, Poland
Novartis Investigative Site
Zabrze, Poland
Novartis Investigative Site
Porto, Portugal
Novartis Investigative Site
Lausanne, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.